Key result
Lingguizhugan decoction significantly reduced serum BNP levels (93.8 vs 169.6 pg/mL) and preserved left ventricular ejection fraction compared to doxorubicin-treated rats.
Why the study?
To investigate whether Lingguizhugan decoction has protective activity and to determine the mechanism underlying its effect in an animal model of heart failure.
Does Lingguizhugan decoction improve cardiac function and TT-SR microstructural remodeling in a rat model of doxorubicin-induced heart failure?
Does Lingguizhugan decoction improve cardiac function and TT-SR microstructural remodeling in a rat model of doxorubicin-induced heart failure?
Absolute Event Rate: 93.8% vs 169.6%
p-value: p=<0.001
Lingguizhugan decoction attenuates doxorubicin-induced heart failure in rats by improving cardiac function and TT-SR microstructural remodeling, potentially via the miR-24/JP-2 pathway.
No takes yet. Share an insight, caveat, or question.
Should not change practice in doxorubicin cardiotoxicity; hypothesis-generating for Lingguizhugan decoction in heart failure models.
Li et al. (2019) studied Doxorubicin-induced heart failure (n=48). Lingguizhugan decoction vs. Doxorubicin + water (model group) was evaluated on Serum BNP level (p=<0.001). Lingguizhugan decoction significantly reduced serum BNP levels (93.8 vs 169.6 pg/mL) and preserved left ventricular ejection fraction compared to doxorubicin-treated rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: